{"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"groups":[{"description":"In Part 1, participants received pembrolizumab 200 mg IV as post-surgery therapy Q3W for up to 1 year.","id":"BG000","title":"Pembrolizumab"},{"description":"In Part 1, participants received placebo IV as post-surgery therapy Q3W.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.6","value":"53.9"},{"groupId":"BG001","spread":"14.2","value":"53.7"},{"groupId":"BG002","spread":"13.9","value":"53.8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"391"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"324"},{"groupId":"BG001","value":"304"},{"groupId":"BG002","value":"628"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"428"},{"groupId":"BG001","value":"425"},{"groupId":"BG002","value":"853"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"PD-L1 Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"116"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"PD-L1 Negative"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"50"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"Undetermined"}],"description":"Tumor PD-L1 status was assessed by immunohistochemistry (IHC) and recorded as positive (≥1% PD-L1 IHC), negative (\\<1% PD-L1 IHC), or undetermined level of expression (indeterminate PD-L1 IHC).","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Death-Ligand 1 (PD-L1) Tumor Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"160"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"Stage IIIA (> 1 mm)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"237"},{"groupId":"BG001","value":"230"},{"groupId":"BG002","value":"467"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"Stage IIIB"},{"categories":[{"measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"188"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"Stage IIIC (1-3 LN+)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"204"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}],"title":"Stage IIIC (≥4 LN+)"}],"description":"Participants were stratified by melanoma stage using the American Joint Committee on Cancer (AJCC) 7th edition stage as follows: Stage IIIA (with \\>1 mm metastasis), Stage IIIB, Stage IIIC with 1-3 positive lymph nodes (LN+), and Stage IIIC with ≥4 LN+.","paramType":"COUNT_OF_PARTICIPANTS","title":"Melanoma Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"75"}],"title":"North America"},{"measurements":[{"groupId":"BG000","value":"341"},{"groupId":"BG001","value":"336"},{"groupId":"BG002","value":"677"}],"title":"Europe"},{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"223"}],"title":"Australia/New Zealand"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"44"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"BG000","value":"514"},{"groupId":"BG001","value":"505"},{"groupId":"BG002","value":"1019"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}]}